First Keytru­da biosim­i­lars move in­to clin­i­cal tri­als as Mer­ck push­es ahead with new for­mu­la­tion

At least three com­pa­nies have start­ed or are about to start tri­als of Keytru­da biosim­i­lars in what’s ex­pect­ed to cre­ate a wave of less ex­pen­sive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.